NEUP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Neuphoria Therapeutics Inc (NEUP) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is currently in a bearish trend with no positive catalysts, weak technical indicators, and a lack of clear direction for the company's future. Additionally, there are no favorable trading signals or recent news to support a buying decision.
The technical indicators for NEUP are bearish. The MACD histogram is negative and contracting, RSI is neutral at 29.107, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 4.443, with key support at 4.061 and resistance at 4.825. The stock has a 70% chance of declining by -8.98% in the next day and -6.87% in the next month.
NULL identified. There are no recent news updates or significant trading trends from hedge funds, insiders, or Congress.
The Phase 3 AFFIRM-1 trial of BNC210 for the treatment of social anxiety disorder did not meet its primary or secondary endpoints. Analysts have downgraded the stock to Neutral, citing an unclear path forward for the company.
No financial data available for analysis.
H.C. Wainwright analyst Joseph Pantginis downgraded NEUP to Neutral from Buy, with no price target. The downgrade is due to the failure of the Phase 3 AFFIRM-1 trial, which has raised concerns about the company's future direction.
